Contraception :: Wyeth’s Lybrel a new oral contraceptive for women
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that two new scientific abstracts relating to the investigational, combination oral contraceptive Lybrel? (90 ?g levonorgestrel/20 ?g ethinyl estradiol tablets) were presented this week at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting in Washington, D.C.